stockrow
Saturday 7 November 2026
Export AKTS’s income statement to Excel — free account
Aktis Oncology, Inc.
AKTS Healthcare Biotechnology
Aktis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.5 million, up 336.9% from fiscal 2024.
15.78
0.93
+6.26%
Follow AKTS
Alert me
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — |
P/S ratio |
0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
3.64 | 2.53 | — |
P/FCF ratio |
0.00 | 0.00 | — |
P/Operating CF |
(0.28) | (0.28) | — |
P/B ratio |
0.00 | 0.00 | — |
Price to Tangible BV |
0.00 | 0.00 | — |
EV/Sales |
0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | — |
EV/Operating CF |
2.51 | 2.51 | — |
EV/FCF |
2.11 | 2.11 | — |
Quick Ratio |
7.26 | 15.79 | 15.69 |
Current Ratio |
7.37 | 15.98 | 16.07 |
Net Debt/EBITDA |
2.95 | 5.45 | 2.66 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.01 | — |
Operating CF/Net income |
1.01 | (0.34) | 1.05 |
Capex/Depreciation |
4.18 | 1.14 | 1.83 |
| 54.48% | 65.59% | 0.00% | |
| (21.56%) | (19.61%) | 0.00% | |
ROIC |
0.00% | 0.00% | (369.71%) |
Return on Tangible Assets |
(29.83%) | (15.20%) | (28.79%) |
Average Days of Receivables |
0.00 | 0.00 | — |
Research and Development Expense of Revenue |
1,038.19% | 2,754.14% | 0.00% |
Selling, General and Administrative Expense of Revenue |
211.33% | 846.20% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
78.97% | 151.98% | 0.00% |
Graham Net Nets |
8.44 | 8.44 | — |
Graham Number |
0.00 | 0.00 | — |
Earnings Yield |
(129.71%) | (129.71%) | — |
Free Cash Flow Yield |
(546.91%) | (546.91%) | — |
Revenue per Share |
7.99 | 2.11 | 0.00 |
Operating CF per Share |
(78.83) | 20.96 | (48.77) |
Capex per Share |
(11.78) | (4.06) | (6.03) |
Free Cash Flow per Share |
(90.61) | 16.90 | (54.80) |
Cash per Share |
278.78 | 421.99 | 159.07 |
Shareholders Equity per Share |
230.19 | (124.68) | 168.63 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
230.19 | (124.68) | 168.63 |
Free Cash Flow |
(73.71) | 11.90 | (33.71) |
Working Capital |
199.07 | 282.03 | 93.97 |
Capital Expenditures |
(9.58) | (2.86) | (3.71) |
Net Current Asset Value |
152.69 | 220.28 | 81.59 |
EV/EBIT |
0.00 | 0.00 | — |
Capex to Sales |
1.48 | 1.92 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | — |
| Other line items | |||
Depreciation/Fixed assets |
(0.16) | (0.34) | (0.37) |
Cash ROIC |
(17.80%) | 5.68% | (16.72%) |
Accounts Receivable Turnover |
0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Payables |
1.83 | 1.44 | — |
Average Assets |
295.53 | 224.27 | — |
Average Common Equity |
(116.98) | (67.05) | — |
Columns are period end dates · fundamentals updated 26 Oct 2026